Tirzepatide (Mounjaro) generally produces larger A1C reductions and more weight loss than Ozempic in head-to-head trial data. Both are weekly injectables approved for type 2 diabetes. The main mechanical difference is that tirzepatide is a dual GIP/GLP-1 receptor agonist, while Ozempic (semaglutide) is a single GLP-1 agonist. Both share similar side-effect profiles and similar serious-risk warnings. Insurance and tolerability often drive the choice between them.
What Each Drug Is
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It was FDA-approved in 2017 for the treatment of type 2 diabetes. Approved doses are 0.25, 0.5, 1, and 2 mg weekly (with the 0.25 mg being the starting dose, not maintenance).
Tirzepatide is the active ingredient in Mounjaro, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. It was FDA-approved in 2022 for the treatment of type 2 diabetes. Approved maintenance doses are 5, 10, and 15 mg weekly (with 2.5 mg being the starting dose).
Both are dosed once weekly via subcutaneous injection. Both are sold in pre-filled pens (Ozempic in multi-dose pens, Mounjaro in single-dose pens).
Head-to-Head: SURPASS-2 Trial
The SURPASS-2 trial randomized 1,879 adults with type 2 diabetes to weekly tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg (Ozempic) for 40 weeks. Tirzepatide outperformed semaglutide on every primary and secondary outcome.
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|---|
| A1C reduction | -2.0% | -2.2% | -2.3% | -1.9% |
| % reaching A1C <7.0% | 82% | 86% | 86% | 79% |
| % reaching A1C <5.7% | 26% | 40% | 46% | 19% |
| Weight reduction | -7.6 kg | -9.3 kg | -11.2 kg | -5.7 kg |
Even the lowest tirzepatide dose (5 mg) outperformed the standard semaglutide dose (1 mg) on most outcomes. Note that the trial did not compare maximum Ozempic dose (2 mg) which was approved later.
Mechanism: Why the Difference?
Both drugs mimic gut hormones (incretins) that regulate blood sugar and appetite, but they target different receptors:
- Ozempic (semaglutide): activates GLP-1 receptors only. GLP-1 stimulates insulin release, slows gastric emptying, reduces appetite, and increases satiety.
- Tirzepatide: activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that works alongside GLP-1 in the natural gut hormone response.
The dual GIP/GLP-1 mechanism is theorized to amplify the metabolic effects beyond what GLP-1 alone produces. The exact contribution of GIP activation is still being studied, but clinical trial outcomes support the additional effect.
Dosing Comparison
| Phase | Ozempic dose | Mounjaro dose |
|---|---|---|
| Weeks 1-4 | 0.25 mg (starting) | 2.5 mg (starting) |
| Weeks 5-8 | 0.5 mg | 5 mg |
| Weeks 9-12 | 1 mg | 7.5 mg |
| Weeks 13-16 | (can stay at 1 mg) | 10 mg |
| Weeks 17-20 | 2 mg (max) | 12.5 mg |
| Weeks 21+ | — | 15 mg (max) |
The mg numbers are not directly comparable — they are different molecules. Tirzepatide’s longer titration period may help tolerability through more gradual dose escalation.
Side Effects
Both drugs share an essentially identical side-effect profile because both signal through GLP-1 receptors. The most common (from SURPASS-2):
| Side effect | Tirzepatide | Semaglutide 1 mg |
|---|---|---|
| Nausea | 17-22% | 17.9% |
| Diarrhea | 13-16% | 11.5% |
| Vomiting | 6-10% | 8.3% |
| Decreased appetite | 10-15% | 9.4% |
| Discontinuation from AE | 5-7% | 4% |
Both carry the same FDA boxed warning about thyroid C-cell tumors based on rodent studies. Both carry risks of pancreatitis, gallbladder disease, and acute kidney injury (from dehydration secondary to GI symptoms).
Cost
List prices are similar:
- Ozempic: ~$968 per month
- Mounjaro: ~$1,069 per month
Insurance coverage varies. Both manufacturers offer savings programs:
- Novo Nordisk Ozempic savings card: commercially insured patients can pay as little as $25 per month
- Eli Lilly Mounjaro savings card: commercially insured patients can pay as little as $25 per month
Eligibility excludes patients on government insurance (Medicare, Medicaid, TRICARE). Patient assistance programs exist for uninsured patients meeting income criteria.
Insurance Coverage Notes
Most commercial plans and Medicare Part D cover Ozempic for type 2 diabetes; coverage of Mounjaro is also widespread. Plans may prefer one over the other based on negotiated rebates. Step therapy is common — your plan may require trying metformin first, or one GLP-1 before approving another.
Which Should You Choose?
For maximum A1C reduction and weight loss, tirzepatide (Mounjaro) outperforms Ozempic in head-to-head data. For practical considerations:
- If your insurance covers Ozempic but not Mounjaro (or vice versa), the covered option is usually the practical choice
- If you’ve used Ozempic and not responded well, Mounjaro is a reasonable next step
- If you’ve had severe side effects on Ozempic, Mounjaro may produce similar issues but with a more gradual titration option
- If cost is your primary concern, run the math with manufacturer savings cards on your specific situation
Both are American Diabetes Association-recommended options for type 2 diabetes when weight loss is also a treatment goal.
The Bottom Line
Tirzepatide (Mounjaro) generally produces larger A1C reductions and more weight loss than Ozempic in head-to-head trials, driven by its dual GIP/GLP-1 mechanism. Both are weekly injections with similar side-effect profiles and similar serious-risk warnings. Insurance coverage and tolerability often drive the choice between them. Consult your prescriber to discuss which fits your specific situation. For more on GLP-1 treatment options, see our hub.
